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Although parathyroidectomy remains the only curative approach to most primary hyperparathyroidism cases, medical treatment
with cinacalcet HCl has been proven to be a reasonable alternative for several patient subgroups. Cinacalcet almostalwayscontrols
hypercalcemia and hypophosphatemia suﬃciently. PTH levels are lowered, and cognitive parameters improve. While an increase
in bone mineral density DEXA scan scores was not demonstrated in cinacalcet trials, the same applies to more than half of
patients after parathyroidectomy. Medical therapy should be ﬁrst choice in patients with hyperplasia in all glands rather than an
isolatedadenoma(10–15%),patientswithpersistingHPT followingunsuccessfulsurgeryorinoperablecasesdue tocomorbidities,
and patients detected in lab screens for hypercalcemia before developing symptoms who should be treated early but are usually
reluctant to undergo surgery. Nephrolithiasis was not found to occur more frequently in cinacalcet trial groups, but urine calcium
excretion asonemajorrisk factorofthiscomplicationofprimaryHPT mayincrease oncinacalcet.Patients carrying thers1042636
polymorphism of the calcium-sensing receptor gene respond more sensitively to cinacalcet and have a higher risk of calcium
stone formation. Cinacalcet is usually administered twice daily but three or four doses per day should be discussed to mimic the
beneﬁcial pulsatile PTH-pattern.
1.Introduction
Since the approval of cinacalcet HCl for the therapy of
secondary hyperparathyroidism (sHPT) and hypercalcemia
due to parathyroid carcinoma in 2004, calcimimetic therapy
has become daily routine especially for clinical nephrologists
worldwide. WhilepHPTwasincludedasanindication bythe
European Drug Agency in June 2008, this has not been the
casesofarintheUS.Thedrugisgenerallywelltolerated,and,
although there is still considerable inter-individual variation
in dose response ratio, this is much less pronounced as com-
pared with the earlier compound R-568, which remained ex-
perimental and was not introduced into clinical practice for
that reason. PTH target ranges can be achieved in about 70%
of secondary HPT patients, adverse events include mainly
nausea, diarrhea, and rarely paresthesias in this patient
population.
From the beginning of the development of this new
class of drugs, calcimimetics have been considered for the
treatment not only of secondary but also of primary HPT.
As early as 1997 Silverberg et al. reported a short-term
inhibition of PTH secretion by R-568 in 20 postmenopausal
women [1]. The ﬁrst evidence of a long-term beneﬁt from
activated calcium-sensing receptor status in primary HPT
patients was provided by a genetic study: Yamauchi et al.
found lower PTH and serum calcium levels in 105 Japanese
pHPT patients with the calcium-sensing receptor poly-
morphism Arg990Gly in 2001, as compared with patients
without the polymorphism [2]. This polymorphism, which
leads to an exchange of arginine by glycine in position 990
of the receptor molecule, results in a permanent allosteric
activation of the receptor. Conformational change of the
receptormolecule leadsto an increased sensitivity tocalcium
ions, which can be further increased due to the transient
eﬀect of a calcimimetic compound binding to the receptor.
One might speculate, that administering a CaSR acti-
vating agent in a state of reduced CaSR expression due to
hypercalcemia—which applies to pHPT—might be ineﬀec-
tive. However, in a murine model with reduced expression
of CaSR in the parathyroid glands, a Japanese group could
show that cinacalcet was still active in these animals despite
low numbers of target receptors and already high calcium2 International Journal of Endocrinology
concentrations. A negative correlation between the potency
ofcinacalcet HCl and CaSRexpression in parathyroid glands
suggested that cinacalcet HCl exerts its eﬀect via CaSR and
that the potency of cinacalcet HCl depends on the degree
of CaSR expression. Even in the CaSR hypoexpression state
induced by severe hyperparathyroidism, the resistance to
CaSR activation was overcome by increasing the dose of
cinacalcet HCl [3].
In this paper, literature regarding cinacalcet therapy in
primary HPT will be reviewed and the decision algorithms
for various patient subgroups will be discussed regarding
parathyroidectomy and cinacalcet or other medical treat-
ment options. The discussion will focus on safety issues,
the main complications of primary HPT (hypercalcemia,
and nephrolithiasis, ﬁbrosing osteitis, neurological com-
plications) as well as genetic risk factors. Since persisting
hyperparathyroidism after kidney transplantation resembles
primary HPT in many ways, this entity will also be covered
in a separate paragraph.
2.Parathyroidectomy
Dillon et al. reviewed the literature regarding the treatment
of pHPT with a focus on cinacalcet. A MEDLINE (1965–
June 2009) and bibliographic search of the English-language
literature was conducted using the search terms cinacalcet,
calcimimetics,primary hyperparathyroidism, andtreatment.
All articles identiﬁed in the search were included.
They concluded that parathyroidectomy is curative for
many patientswithpHPT;however, thereare furtheroptions
for several patient subgroups as follows:
(1) patients who are not surgical candidates or who
refuse surgery,
(2) those with refractory pHPT after parathyroidectomy,
(3) patients who are asymptomatic and therefore unwill-
ing to undergo surgery although they would beneﬁt
from it.
Cinacalcet may be considered to reduce serum calcium
and parathyroid hormone serum levels in patients with
pHPT who cannot undergo surgery or are unwilling to do
so and those with refractory pHPT after parathyroidectomy.
As the eﬀects of cinacalcet on bone mineral density are un-
certain, and bone biopsies are rarely available, more frequent
monitoring of bone mineral density may be an option. The
authors recommend future studies to evaluate the eﬀect of
cinacalcet on complications of pHPT [4].
In 80% of cases, pHPT is due to a single parathyroid
adenoma, for which surgery is considered the treatment
of choice based on guidelines established by the National
Institutes of Health Consensus Panel. However, since success
rates of the operation are less than 100% and vary between
centers, pharmacotherapy with agents such as cinacalcet
could be an alternative in a subset of patients with persistent
hypercalcemia after one or more surgical interventions [5].
Indications for parathyroidectomy according to the NIH
consensus include a DEXA scan T score less than −2.5
standard deviations from the mean, serum calcium 1mg/dL
above the upper limit of normal, 24-hour urine calcium
above 400mg/24h, age less than 50 years, or a creatinine
clearance that is 30% below age- and sex-matched controls.
However, at present many patients are identiﬁed at earlier
stages of the disease. As these patients often have cognitive
impairment and latent depression theywould already beneﬁt
from an early parathyroidectomy in terms of quality of life
as measured by the SF-36 questionnaire [6], but, because of
relatively few symptoms most of them are unwilling to have
surgery performed.
Presently, no data are available on bone biopsy results in
pHPT patients treated with cinacalcet and no improvement
in bone mineral density scores was found. But the same
applies to parathyroidectomy, which also fails to achieve
higher DEXA scores in many cases: In a study with post-
menopausal women with pHPT the score had remained
unchanged orevendecreased one yearafter surgery in 52 out
of 103 patients [7].
Obviously the risk of general anaesthesia must be
considered in all operations. This risk varies highly between
centers and geographical locations. Death rates from airway
complications during general anaesthesia may be very low
at 1:48200 throughout France [8], but anaesthesia-related
mortality can be 100 times higher than that (1:482) in a
district hospital in the developing world [9].
3.ControllingHPTComplications
3.1. Hypercalcemia. All studies conﬁrm that cinacalcet eﬀec-
tively controls hypercalcemia while only modestly reducing
PTH levels in pHPT. As Sajid-Crocket et al. point out,
primary hyperparathyroidism (HPT) is the leading cause
of hypercalcemia in the outpatient setting, and it is treated
primarily by parathyroidectomy. They conducted a retro-
spective chart review from 2004 to 2006 to investigate the
eﬃcacy of cinacalcet in reducing serum totalcalciumionized
calcium, and parathyroid hormone (PTH) in patients with
primary HPT. Patients were started on cinacalcet if they met
at least one indication for parathyroidectomy. The primary
outcome was normalization of serum calcium. A total of 18
patients with primary HPT were started on cinacalcet: 16
men and 2 women with a mean age of 70 years. Mean base-
line serum calcium was 10.60 ± .53mg/dL; ionized serum
calcium was 1.45 ± .07mmol/L; and serum PTH was 141 ±
78pg/mL. After treatment with cinacalcet, the mean serum
calcium decreased to 9.46 ± 3.4mg/dL, ionized calcium
decreasedto1.26 ± .06mmol/L,and PTHdecreasedto108±
64.5pg/mL.Ninety-four percentofthepatientsoncinacalcet
had normal total serum calcium, 81% had normal serum
ionizedcalcium,whereas only25%hadanormal serumPTH
level. Cinacalcet normalizes serum calcium in most patients
while only modestly reducing serum PTH levels [10].
The group of Peacock and Shoback found successful and
persistent control of hypercalcemia in two studies, including
a long-term study lasting up to 5 years. [11, 12]
Cinacalcet was eﬀective in normalizing calcium and
phosphorus concentrations in patients with persistent pHPT
after unsuccessful parathyroidectomy [13].International Journal of Endocrinology 3
The treatment was well tolerated. Highest doses were
reported by Marcocci et al. [14], who enrolled patients
with otherwise intractable pHP T( d e ﬁ n e da se i t h e rf a i l e do r
contraindicatedsurgery)in23centresinEurope,theUS,and
Canada. They administered up to 90mg cinacalcet 4 times
perday.Althoughmetabolized primarily in the liver, cinacal-
cet was successfully used in a patient with Child-Pugh B class
primary biliary cirrhosis who refused to have surgery [15].
Possible medical treatment options for pHPT-induced
hypercalcemia include estrogens, raloxifene, bisphospho-
nates, and calcitonin, apart from cinacalcet.
3.2. Hyperphosphaturia. Hyperphosphaturia is one of the
features of hyperparathyroidism and contributes to hypo-
phosphatemia and ﬁbrosing osteitis. Parathormone upregu-
lates ﬁbroblast growth factor 23 (FGF-23) and several other
so-called phosphatonins (phosphaturic peptides), which in
turn inhibit Na(+)-Phos(i) transporters in renal epithelial
cells and reduce phosphate reabsorption from the proximal
tubuli. [16]. Cinacalcet was found to reduce hyperphospha-
turia and increase serum phosphate levels into normal or
almost normal ranges in all studies.
3.3. Fibrosing Osteitis. This complication of pHPT is the
most long-term one. The duration of followup in the longest
study on cinacalcet in pHPT patients conducted so far
was 5 years: Peacock et al. examined long-term tolerability,
safety, and eﬃcacy of cinacalcet in pHPT patients including
bone parameters in a 4.5-year open-label extension study,
conducted at 14 study centers in the United States. Forty-
ﬁve subjects with pHPT from a double-blind, placebo-
controlled, 1-year trial were continued into this study. After
theparent study, all subjectswere treated with30mg cinacal-
cet twice daily, increasing to 50mg twice daily during the 12-
week titration phase if serum calcium levelswere 10.3mg/dL
or higher and then maintained on cinacalcet for up to 4.5
years. Assessments includedserum calcium,PTH, phosphate
and alkaline phosphatase, and area bone mineral density
(aBMD). Vital signs, safety chemistries and hematology, and
adverse events were monitored throughout. Compared with
baseline, cinacalcet treatment improved biochemical mea-
sures of pHPT including reducing serum calcium and PTH
andincreasing serum phosphatewithslightincreases inalka-
line phosphatase. No changes in z-scores of aBMD at spine,
hip, or wrist were seen with annual percent changes, consis-
tent with reports for untreated postmenopausal women or
pHPT patients. Safety biochemistries remained normal, and
adverse events (most commonly arthralgia, myalgia, diar-
rhea, respiratory infection, and nausea) were mild to mod-
erate in severity. In conclusion, treatment of pHPT patients
with cinacalcet for up to 5.5 years maintained normocal-
cemia, reduced plasma PTH, increased serum phosphate to
almost normal levels (due to reduction of hyperphospha-
turia) with no signiﬁcant eﬀects on aBMD, and was well
tolerated [17]. The fact that alkaline phosphatase increased
overtimeinthisstudyprobablyreﬂectstheongoingcourseof
the disease, including continuous bone repair mechanisms.
Severe bone pain due to primary HPT has become a rare
event,sincetheconditioniscurrentlydiagnosedmuchearlier
than it used to be. In clinical trials with secondary HPT,
cinacalcet was found to be very eﬀective for PTH-induced
bone pain. Parathormone stimulates bone remodelling and
FGF-23 synthesis in the bone. In conclusion a beneﬁcial
eﬀect still has to be proven in bone biopsy studies, but
the calcium controlling eﬀect was maintained over long-
term administration and parathyroidectomy fails to achieve
increased BMD scores in most patients, too, especially in
post-menopausal women.
3.4. Nephrolithiasis. At this point it is necessary to explain
the mode of action of calcimimetic therapy in the renal
tubules. While the calcium-sensing receptor is expressed
almost ubiquitously, crucial locations in HPT therapy are
the parathyroid glands, the intestine (to control calcium
resorption) and the kidneys. Calcimimetics act as allosteric
activators of the CaSR, enhancing its sensitivity towards
calcium ions: in the renal tubules, this leads to decreased
calcium reabsorption.
The fact that activation of the CaSR in the renal
tubules triggers calciuria with subsequently elevated risk
of nephrolithiasis can be neglected in a state of renal
insuﬃciency such as secondary HPT but not in primary
HPT or persisting HPT after kidney transplantation. A
simultaneous decrease of PTH and serum calcium levels
due to the therapy apparently balances out this tendency
towards hypercalciuria in many patients as, for example,
one study found that cinacalcet safely normalized serum
calciumand lowered PTH concentrationswithout increasing
urinary calcium excretion in the study subjects, indicating
the potential beneﬁt of cinacalcet as a medical treatment for
primary hyperparathyroidism [10]. Several other studies did
ﬁnd an increased 24h excretion of urinary calcium, while at
the same time the morning fasting urine calcium/creatinine
ratio was decreased, which might be attributed to the
slight diuretic eﬀect of cinacalcet in subjects with normal
renal function [11]. However, the PTH decreasing eﬀect
is much less pronounced than the calcium lowering ef-
fect.
In the long-term study conducted by Peacock et al., 2
out of 45 patients (4%) developed nephrolithiasis. Genetic
data of these patients were not reported, but we do know
that patients with the Arg990Gly polymorphism, which
leads to permanently increased sensitivity of the CaSR,
have been found to carry an increased risk of calcium
stone formation [18]. Moreover, these patients respond
more strongly to cinacalcet as compared to patients without
the polymorphism [19, 20], so that an increased risk of
nephrolithiasisduetocalcimimetictherapyforpHPTcannot
be ruled out especially in this patient population. Apart
from cinacalcet, possible medical treatment options include
estrogens, raloxifene, bisphosphonates, calcitonin.
3.5. Cognitive Parameters. Primary HPT impairs cognitive
function even before clinical symptoms are noticed by the
patient. These symptoms may resemble depression with4 International Journal of Endocrinology
memory deﬁcits, mood changes and sleeping problems. In
a study, early parathyroidectomy improved scoring in cogni-
tive assessment questionnaires [5]. Similarly, cinacalcet was
also able to improve health-related quality of life (HRQOL)
scores, too, including cognitive tests as compared to the
placebo group.
4.GeneticRiskFactorsInterferingwith
CalcimimeticTherapy
The genetic background of pHPT patients does inﬂuence
the decision which therapy to choose. Sporadic nonfamilial
parathyroidadenomas,associatedwiththecyclinD1/PRAD1
oncogene [17], are the classical indication for surgery, while
hypercalcemia due to hyperplasia in all parathyroid glands
as in the MEN1 syndrome (associated with MEN1 tumor
suppressor gene) could be treated with cinacalcet.
Regarding secondary hyperparathyroidism, there are sig-
niﬁcant diﬀerences in the progression of the disease between
patients of diﬀerent ethnicities: while black patients require
higher vitamin D doses than non-blacks [21], Asian patients
show slower progression of the disease than non-Asians with
the same stages of renal insuﬃciency [22].
Even though no mutations of the calcium-sensing recep-
tor gene have been found in parathyroid adenomas so far
[17], the Arg990Gly polymorphism of this gene is important
for calcimimetic pHPT therapy as a risk factor for nephro-
lithiasis. It is important to note that the glycine allele of this
polymorphism, which renders the receptor more sensitive to
calcium ions, is the most common allele (>90%) in Asians.
Patients with Arg990Gly have better outcomes in pHPT
[2]—it is intriguing to speculate, that the slower progression
in Asian secondary HPT patients is due to their carrying the
more sensitive CaSR allele.
Calcium nephrolithiasis is genetically determined [23],
and since pHPT is the most common cause of this condition
apart from renal tubular acidosis, it should be considered
when planning the therapy.
5.PersistingHyperparathyroidismafter
KidneyTransplantation
This condition is a clear indication for calcimimetic therapy,
since untreated it results in permanent damage to the bones
and parathyroidectomy is an unnecessary operative risk in
these immunosuppressed patients: after one year cinacalcet
can usually be discontinued [24]. Additionally, parathy-
roidectomy often either fails to control hypercalcemia or
leadstopermanent hypoparathyroidism with all related risks
for graft and patient survival. Recently an improvement in
bone density by cinacalcet was reported for this patient
population [25]. From the clinical perspective, the disease
develops from secondary HPT, but it resembles pHPT in
that it leads to hypo- rather than hyperphosphatemia due to
increased phosphaturia.
6.Conclusion
Although parathyroidectomy remains the only curative
approach to the majority of pHPT cases, medical treatment
with cinacalcet HCl has been proven to be a reasonable
alternative for several patient subgroups. Hypercalcemia as
the main clinical issue can almost always be suﬃciently
controlled as well as hypophosphatemia, PTH levels may
be lowered, and cognitive as well as HRQOL parameters
improve with the treatment. An increase in bone mineral
density DEXA scan scores was not demonstrated in pHPT
cinacalcet trials, the same applies to more than half of
patients after parathyroidectomy. In 10–15% of patients the
etiology of primary HPT is hyperplasia in all glands rather
than a separate adenoma, so that medical therapy is ﬁrst
choice in these patients. An increasing proportion ofpatients
are detected in lab screens showing hypercalcemia before
developingsymptoms. These patientsshould be treated early
however; they are generally reluctant to undergo surgery
as they are a- or oligosymptomatic. Other patients with
persisting HPT after failed surgery or inoperable ones due
to co-morbidities should also be oﬀered medical therapy.
Nephrolithiasis occurred in 4% of patients receiving
cinacalcet long-term for pHPT. It was not found to occur
more often in cinacalcet trial groups in several short-term
studies, but urine calcium excretion as one major risk factor
of this complication of primary HPT may increase with
cinacalcet therapy. Patients with the Arg990Gly polymor-
phism of the calcium-sensing receptor, who carry a higher
risk ofcalciumstoneformation andrespondmoresensitively
to cinacalcet, should therefore be oﬀered alternative medical
treatment optionssuchasbisphosphonates,calcitonin,estro-
gen, or raloxifene.
The dosing patterns are also debatable. While most trials
used twice daily dosing of cinacalcet, an increased frequency
of three or four doses per day would mimic the pulsatile
PTH-pattern which has been found to be beneﬁcial for the
prevention of PTH induced osteopathy [26].
In summary, the statement of Franceschini et al. [27],
which they made in their early review article in 2003, has
passed the test of time: cinacalcet HCl is indeed an agent
not only for the management of secondary but also primary
hyperparathyroidism.
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